These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 12597158)

  • 41. Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy.
    Meng X; Huang Z; Teng F; Xing L; Yu J
    Cancer Treat Rev; 2015 Dec; 41(10):868-76. PubMed ID: 26589760
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?
    Festino L; Botti G; Lorigan P; Masucci GV; Hipp JD; Horak CE; Melero I; Ascierto PA
    Drugs; 2016 Jun; 76(9):925-45. PubMed ID: 27229745
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Neoadjuvant trials could speed up drug approvals.
    Peres J
    J Natl Cancer Inst; 2014 Mar; 106(3):dju072. PubMed ID: 24610911
    [No Abstract]   [Full Text] [Related]  

  • 44. [Not Available].
    López-Brea M
    Med Clin (Barc); 2016 Apr; 146 Suppl 1():1. PubMed ID: 27426240
    [No Abstract]   [Full Text] [Related]  

  • 45. JAMA Oncology Patient Page. The Evolution of a Cancer.
    West HJ; Jin JO
    JAMA Oncol; 2015 Sep; 1(6):850. PubMed ID: 26247697
    [No Abstract]   [Full Text] [Related]  

  • 46. PD-L1 Testing in Cancer: Challenges in Companion Diagnostic Development.
    Hansen AR; Siu LL
    JAMA Oncol; 2016 Jan; 2(1):15-6. PubMed ID: 26562503
    [No Abstract]   [Full Text] [Related]  

  • 47. Predictive biomarkers: identification and verification.
    Yeatman TJ
    J Clin Oncol; 2009 Jun; 27(17):2743-4. PubMed ID: 19332709
    [No Abstract]   [Full Text] [Related]  

  • 48. Introducing the BECT (biologically enhanced cytotoxic treatment) concept in cancer treatment.
    Bernier J; Bourhis J
    Ann Oncol; 2005 Nov; 16(11):1722. PubMed ID: 16087695
    [No Abstract]   [Full Text] [Related]  

  • 49. [Evolution of the parameters indicating response to drug therapy: from regression to complete control of the disease and the symptoms].
    Cascinu S; Camisa R; D'Angelo A; Salvagni S
    Tumori; 2002; 88(6):A7-9. PubMed ID: 12597158
    [No Abstract]   [Full Text] [Related]  

  • 50. [Rationales for the integration of molecular and conventional therapies].
    Tortora G; Ciardiello F
    Tumori; 2002; 88(6):A9-13. PubMed ID: 12597159
    [No Abstract]   [Full Text] [Related]  

  • 51. Clinical significance of epithelial-mesenchymal transition and cancer stem cells.
    Topcul M; Cetin I
    J BUON; 2016; 21(2):312-9. PubMed ID: 27273939
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cancer stem cell targeted therapy: progress amid controversies.
    Wang T; Shigdar S; Gantier MP; Hou Y; Wang L; Li Y; Shamaileh HA; Yin W; Zhou SF; Zhao X; Duan W
    Oncotarget; 2015 Dec; 6(42):44191-206. PubMed ID: 26496035
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical aspects for survivin: a crucial molecule for targeting drug-resistant cancers.
    Singh N; Krishnakumar S; Kanwar RK; Cheung CH; Kanwar JR
    Drug Discov Today; 2015 May; 20(5):578-87. PubMed ID: 25433305
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pragmatic issues in biomarker evaluation for targeted therapies in cancer.
    de Gramont A; Watson S; Ellis LM; Rodón J; Tabernero J; de Gramont A; Hamilton SR
    Nat Rev Clin Oncol; 2015 Apr; 12(4):197-212. PubMed ID: 25421275
    [TBL] [Abstract][Full Text] [Related]  

  • 55.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 56.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.